ATP inhibits NMDA receptors after heterologous expression and in cultured hippocampal neurons and attenuates NMDA-mediated neurotoxicity.
We investigated the potential of ATP to inhibit heterologously expressed NMDA receptor subunit combinations, NMDA-induced currents in cultured hippocampal cells, and NMDA-induced neurotoxicity. The effect of ATP on diheteromeric NR1a/NR2A-D NMDA receptor (NR) combinations expressed in Xenopus laevis oocytes was studied by voltage-clamp recording. ATP strongly inhibited NMDA-induced inward currents only at the NR1a/NR2B receptor combination. At NMDA concentrations corresponding to the EC50 value (20 microm), ATP revealed an IC50 value of 135 microm. Mutation studies suggest that ATP exerts its inhibition via the glutamate-binding pocket of the NR2B subunit. Inosine 5'-triphosphate (ITP), GTP, and AMP also inhibited the recombinant NR1a/NR2B receptor, whereas UTP and CTP, ADP, or adenosine had no or only a small effect. Correspondingly, ATP inhibited NMDA-induced but not kainate-induced currents at cultured hippocampal neurons. An abundant expression of the NR2B subunit in the cultured neurons was verified by immunocytochemistry and blockade of NMDA-induced currents by the NR2B-selective antagonist ifenprodil. In addition we studied the role of ATP in NMDA-mediated neurotoxicity using cultured rat hippocampal cells. ATP exhibited a dose-dependent rescue effect when coapplied with the excitotoxicant NMDA, in contrast to ADP, AMP, and adenosine. The effect of ATP was mimicked by GTP and ITP but not by UTP and CTP. ATP had no effect on kainate-elicited neurotoxicity. Our results suggest that ATP can act as an inhibitor of NMDA receptors depending on receptor subunit composition and that it can attenuate NMDA-mediated neurotoxicity that is mediated neither by ATP nor by adenosine receptors.
Ortinau
Stefanie
S
Biozentrum der J. W. Goethe-Universität, Arbeitskreis Neurochemie, Zoologisches Institut, D-60439 Frankfurt am Main, Germany.
Laube
Bodo
B
Zimmermann
Herbert
H
D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity; D006624:Hippocampus / Q000166:cytology / Q000378:metabolism*; D007608:Kainic Acid / Q000633:toxicity; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors* / Q000633:toxicity; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology; D009711:Nucleotides / Q000494:pharmacology; D009865:Oocytes / Q000378:metabolism; D018408:Patch-Clamp Techniques; D021122:Protein Subunits / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D058919:Purinergic P2 Receptor Antagonists; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D014982:Xenopus laevis
D018690:Excitatory Amino Acid Agonists; D018696:Neuroprotective Agents; D009711:Nucleotides; D021122:Protein Subunits; D058919:Purinergic P2 Receptor Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; D000255:Adenosine Triphosphate; D000241:Adenosine; D007608:Kainic Acid